Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Stoke Therapeutics Inc (STOK)

Stoke Therapeutics Inc (STOK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire - Thu Apr 16, 3:01PM CDT

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 35.61 (-2.33%)
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference Business Wire - Wed Apr 8, 3:01PM CDT

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 35.61 (-2.33%)
BIIB : 185.95 (+1.42%)
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors Business Wire - Tue Apr 7, 3:01PM CDT

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 35.61 (-2.33%)
BIIB : 185.95 (+1.42%)
Stoke Therapeutics Faces Mounting Losses as Earnings Loom Barchart - Tue Mar 24, 4:06PM CDT

STOK : 35.61 (-2.33%)
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire - Tue Mar 17, 4:12PM CDT

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 35.61 (-2.33%)
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome Business Wire - Wed Mar 4, 4:06PM CST

–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– ...

STOK : 35.61 (-2.33%)
BIIB : 185.95 (+1.42%)
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome GlobeNewswire - Wed Mar 4, 4:05PM CST

–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– –Data support...

STOK : 35.61 (-2.33%)
BIIB : 185.95 (+1.42%)
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference Business Wire - Tue Feb 24, 3:01PM CST

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine,...

STOK : 35.61 (-2.33%)
BIIB : 185.95 (+1.42%)
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire - Wed Feb 18, 3:01PM CST

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 35.61 (-2.33%)
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA) Business Wire - Wed Feb 11, 6:30AM CST

–Dose-escalating study will evaluate the safety, tolerability and exposure of STK-002 in people with ADOA– –Changes in visual function, ocular structure and quality of life...

STOK : 35.61 (-2.33%)

Barchart Exclusives

2 Warren Buffett Dividend Stocks to Scoop Up in April Barchart - Tue Apr 21, 6:30PM CDT
Warren Buffett is known for favoring durable businesses with strong cash flows, the kind that can sustain and grow dividends over time. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.